Skip to content

Necrotizing External Otitis : Study in a Regional Bone and Joint Infection Reference Center

Necrotizing External Otitis : Study in a Regional Bone and Joint Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03768635
Enrollment
53
Registered
2018-12-07
Start date
2006-01-01
Completion date
2018-07-31
Last updated
2018-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Joint Infection

Keywords

otitis

Brief summary

The malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. To our knowledge, there are few data and it is not wellc known byclinicians. Nevertheless it exposes to neurological complications potentially serious and crippling.

Interventions

OTHERnecrotizing external otitis

description of necrotizing external otitis

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years

Inclusion criteria

* patients having had necrotizing external otitis and managed at the Lyon Bone and joint infection refence Center

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Rate of necrotizing external otitisOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptiondescription of necrotizing external otitis: patients, profile of the bacterium, medical and chirurgical treatment, rate

Secondary

MeasureTime frameDescription
Rate of Treatment FailureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionTreatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor.
Duration of antibioticsOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionDescription of the strategies of antibiotic treatments used (double-agent therapy, monotherapy, duration)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026